European Investor
18 Apr 2026, 20:17
Abbott announced new clinical data demonstrating progress in its Cancerguard multi-cancer early detection (MCED) test at the 2026 American Association for Cancer Research (AACR) Annual Meeting, highlighting improved early-stage cancer detection using a multi-biomarker approach.
The data show that combining methylation and protein biomarkers enhances detection across cancer types and stages, with each biomarker contributing independently. In a case-control study, nearly half of detected cancer signals came from methylation alone, while additional cases were identified through protein-only and combined biomarker signals, supporting broader and earlier detection.
Separately, long-term results from the DETECT-A study—recognized with an AACR award—demonstrated the potential clinical impact of blood-based MCED testing. The study identified multiple cancer types, including those without routine screening, and reported that patients diagnosed at early stages remained alive and cancer-free after several years of follow-up.
Abbott emphasized that multi-cancer early detection could play a significant role in improving screening, particularly as a large proportion of cancers currently lack standard screening methods. The Cancerguard test, which uses a simple blood draw, is designed to detect multiple cancers at early stages, though it has not yet received regulatory approval.
PRNewswire
The data show that combining methylation and protein biomarkers enhances detection across cancer types and stages, with each biomarker contributing independently. In a case-control study, nearly half of detected cancer signals came from methylation alone, while additional cases were identified through protein-only and combined biomarker signals, supporting broader and earlier detection.
Separately, long-term results from the DETECT-A study—recognized with an AACR award—demonstrated the potential clinical impact of blood-based MCED testing. The study identified multiple cancer types, including those without routine screening, and reported that patients diagnosed at early stages remained alive and cancer-free after several years of follow-up.
Abbott emphasized that multi-cancer early detection could play a significant role in improving screening, particularly as a large proportion of cancers currently lack standard screening methods. The Cancerguard test, which uses a simple blood draw, is designed to detect multiple cancers at early stages, though it has not yet received regulatory approval.
PRNewswire
